Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he was a graduate student at The Rockefeller University where he earned his PhD in chemical biology. His research has ranged from working in the nanoscience department at Sandia National Lab to studying small molecule inhibitors of bacterial infection. He obtained a BS in chemistry and molecular biology from Harvey Mudd College.